Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
This agreement builds on a clinical collaboration between the companies under which amezalpat was combined with atezolizumab and bevacizumab in first-line HCC patients and compared to atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study.Tempest Therapeutics Inc. (NASDAQ:TPST) stock is trading higher on Thursday, with a strong session volume of over 23 million as per data from Benzinga Pro.
Tempest Therapeutics Inc.（納斯達克：TPST）股票週四交投較高，成交量超過2300萬，數據來源於Benzinga Pro。
The company entered into an agreement with Roche Holdings AG (OTC:RHHBY) to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a Phase 3 trial for the first-line treatment of liver cancer.
該公司與Roche Holdings AG（場外交易：RHHBY）達成協議，推進amezalpat（TPSt-1120）與atezolizumab（Tecentriq）和bevacizumab的聯合評估，後者是不可切除或轉移性肝細胞癌（HCC）的當前標準治療方案，進入第3期臨床試驗，用於肝癌的一線治療。
Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study.
根據協議，Roche將全球供應atezolizumab，而Tempest將贊助並領導這一關鍵研究。
This agreement builds on a clinical collaboration between the companies under which amezalpat was combined with atezolizumab and bevacizumab in first-line HCC patients and compared to atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study.
該協議構建在兩家公司之間的臨床合作基礎上，根據該合作將amezalpat與atezolizumab和bevacizumab結合用於一線HCC患者，並在隨機的第1b/2期研究中與atezolizumab和bevacizumab單獨進行比較。
Tempest retains all development and commercial rights to amezalpat.
Tempest保留amezalpat的所有開發和商業權利。
"Based on the positive Phase 2 data, I believe this combination therapy holds the potential to significantly improve first-line liver cancer treatment, and we look forward to amezalpat moving into this pivotal Phase 3 study," said Stephen Brady, president and CEO of Tempest.
「基於積極的第2期數據，我相信這種聯合治療有可能顯著改善肝癌的一線治療，我們期待amezalpat進入這一關鍵的第3期研究，」Tempest的總裁兼首席執行官Stephen Brady表示。
In June, Tempest reported updated survival data from the ongoing global randomized Phase 1b/2 study, demonstrating a six-month improvement in median overall survival (OS) for patients receiving the combination therapy compared to the control arm of atezolizumab and bevacizumab alone.
6月，Tempest公佈了來自進行中的全球隨機第1b/2期研究的最新生存數據，顯示接受聯合治療的患者的中位總生存期（OS）比僅接受atezolizumab和bevacizumab的對照組有6個月的改善。
The survival benefit observed in the amezalpat arm was also maintained in key subpopulations.
amezalpat組觀察到的生存益處也在關鍵亞人群中得以保持。
These June data build upon previously released data from the primary analysis showing that the amezalpat combination therapy provided clinical benefit regardless of PD-L1 status and in patients with both immune excluded and immune desert tumors.
這些六月的數據基於之前發佈的主要分析數據，顯示阿米扎帕特聯合療法無論PD-L1狀態如何，都能爲免疫排斥和免疫荒漠腫瘤患者提供臨床益處。
Patients with a mutation in the beta-catenin gene had an increased objective response rate, and a longer median OS was observed in the updated data set. Both were supported by amezalpat's purported mechanism of action.
具有beta-連接蛋白基因突變的患者具有增加的客觀反應率，在更新的數據集中觀察到更長的中位生存期。這兩者都得到了阿米扎帕特所聲稱的作用機制的支持。
The company is preparing for the Phase 3 study to start in the first quarter of 2025.
該公司準備在2025年第一季度開始進行第三階段研究。
Price Action: TPST stock is up 23% at $1.66 during the premarket session at last check Thursday.
股票TPSt的價格表現在週四的盤前交易中上漲了23％，至1.66美元。
Photo via Shutterstock
圖片來自shutterstock。
- Delta's Turbulent Q3: Mixed Results And Tech Troubles Cloud Holiday Outlook.
- 德爾塔公司動盪的第三季度：業績參差不齊，技術問題蒙上節日前景的陰影。
譯文內容由第三人軟體翻譯。
